Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Tafasitamab in Previously Treated Marginal Zone Lymphomas
NCT04646395Phase 2Active, not recruiting
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of tafasitamab, acalabrutinib in marginal zone lymphoma (MZL), sponsored by International Extranodal Lymphoma Study Group. Started Oct 2021; status: active, not recruiting.
02
Drugs
tafasitamabacalabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04646395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646395.